Gyre Therapeutics (GYRE) Proxy filing summary

Executive summary

• The annual meeting is scheduled for June 10, 2026, to be held virtually, with voting on four key proposals including director elections, executive compensation, auditor ratification, and approval of Series B Preferred Stock conversion related to the Cullgen merger.

• The Cullgen merger, valued at approximately $300 million, is expected to close in early Q2 2026, making Cullgen a wholly owned subsidiary and introducing new leadership and board changes.

• Forward-looking statements highlight risks and uncertainties, especially regarding regulatory approvals and business operations in the PRC.

Voting matters and shareholder proposals

• Proposals include electing two Class II directors, a non-binding advisory vote on executive compensation, ratification of Grant Thornton as auditor, and approval of Series B Preferred Stock conversion.

• Board recommends voting FOR all proposals and director nominees.

• Shareholders of record as of April 16, 2026, are eligible to vote, with each share entitled to one vote per proposal.

• Procedures for proxy voting, revocation, and quorum requirements are detailed, with preliminary results announced at the meeting and final results filed on Form 8-K.

Board of directors and corporate governance

• The board consists of eight members divided into three classes, with two Class II directors up for election; post-merger, the board will reduce to seven members.

• Board committees include Audit, Compensation, and Nominating, each with defined responsibilities and independent membership where required.

• Controlled company status under Nasdaq rules allows certain governance exemptions due to majority ownership by GNI Japan.

• Director independence is assessed per Nasdaq standards; several directors are independent, while others are not due to executive roles or relationships.

• Corporate governance guidelines, code of ethics, and stockholder communication policies are in place.